Docetaxel, cisplatin and gemcitabine as first line for patients with advanced/metastatic head and neck cancer von Kouroussis, C. H., Androulakis, N., Boukovinas, J., Agelaki, S., Vamvakas, L., Syrigos, K., Potamianou, A., Christophillakis, C. H., Tselepatiotis, E., Helis, L., Polyzos, A.

Volltext

A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer von Stathopoulos, G. P., Aravantinos, G., Syrigos, K., Kalbakis, K., Karvounis, N., Papakotoulas, P., Boukovinas, J., Potamianou, A., Polyzos, A., Christophillakis, C. H., Georgoulias, V.

Volltext

Safety and immunogenicity of the optimized cryptic peptide TERT 572Y in patients with advanced malignancies: A Phase I clinical study von Kosmatopoulos, K., Bolonaki, E., Cornet, S., Nikoloudi, E., Kanellou, P., Millaki, G., Miconnet, I., Christophillakis, C. H., Spiropoulou, M., Georgoulias, V., Mavroudis, D.

Volltext